Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Bariatric Surgery

Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass

International Journal of Obesity volume 36, pages 379–384 (2012)Cite this article

Abstract

Background:

Patients show an elevated postprandial satiety gut hormone release after Roux-en-Y Gastric bypass (gastric bypass). The altered gut hormone response appears to have a prominent role in the reduction of appetite and body weight (BW) after gastric bypass. Patients with insufficient BW loss after gastric bypass have an attenuated postprandial gut hormone response in comparison with patients who lost an adequate amount of BW. The effects of additional gut hormone administration after gastric bypass are unknown.

Methods:

The effects of peripheral administration of peptide YY3-36 (PYY3-36; 300 nmol kg−1), glucagon-like peptide-1 (GLP-1) analogue Exendin-4 (20 nmol kg−1) and somatostatin analogue octreotide (10 μg kg−1) on feeding and BW were evaluated in rats after gastric bypass.

Results:

Gastric bypass rats weighed (P<0.01) and ate less on postoperative day 5 (P<0.001) and thereafter, whereas postprandial plasma PYY and GLP-1 levels were higher compared with sham-operated controls (P<0.001). Administration of both PYY3-36 and Exendin-4 led to a further decrease in food intake in bypass rats compared with saline treatment (P=0.02 and P<0.0001, respectively). Similar reduction in food intake was observed in sham rats (P=0.02 and P<0.001, respectively). Exendin-4 treatment resulted in a significant BW loss in bypass (P=0.03) and sham rats (P=0.04). Subsequent treatment with octreotide led to an increase in food intake in bypass (P=0.007), but not in sham rats (P=0.87).

Conclusion:

Peripheral administration of PYY3-36 and Exendin-4 reduces short-term food intake, whereas octreotide increases short-term food intake in rats after gastric bypass. The endogenous gut hormone response after gastric bypass can thus potentially be further enhanced by additional exogenous therapy with pharmacological doses of gut hormones in patients with insufficient weight loss or weight regain after surgery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Sjostrom L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741–752.

    Article  Google Scholar 

  2. Ashrafian H, le Roux CW . Metabolic surgery and gut hormones—a review of bariatric entero-humoral modulation. Physiol Behav 2009; 97: 620–631.

    Article  CAS  Google Scholar 

  3. Tadross JA, le Roux CW . The mechanisms of weight loss after bariatric surgery. Int J Obes (Lond) 2009; 33 (Suppl 1): S28–S32.

    Article  Google Scholar 

  4. Bueter M, Löwenstein C, Olbers T, Wang M, Cluny NL, Bloom SR et al. Gastric bypass increases energy expenditure in rats. Gastroenterology 2010; 138: 1845–1853.

    Article  Google Scholar 

  5. Orlando FA, Goncalves CG, George ZM, Halverson JD, Cunningham PR, Meguid MM . Neurohormonal pathways regulating food intake and changes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1: 486–495.

    Article  Google Scholar 

  6. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780–785.

    Article  Google Scholar 

  7. le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg 2010; 252: 50–56.

    Article  Google Scholar 

  8. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108–114.

    Article  Google Scholar 

  9. Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 2004; 28: 963–971.

    Article  CAS  Google Scholar 

  10. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650–654.

    Article  CAS  Google Scholar 

  11. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL . Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146: 3748–3756.

    Article  CAS  Google Scholar 

  12. Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM . Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 2011; 19: 121–127.

    Article  CAS  Google Scholar 

  13. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C . Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 2010; 92: 810–817.

    Article  CAS  Google Scholar 

  14. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59: 1635–1639.

    Article  CAS  Google Scholar 

  15. Bueter M, Löwenstein C, Ashrafian H, Hillebrand J, Bloom SR, Olbers T et al. Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass. Obes Surg 2010; 20: 616–622.

    Article  Google Scholar 

  16. Batterham RL, Cohen MA, Ellis SM, le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941–948.

    Article  CAS  Google Scholar 

  17. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR . Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166–170.

    Article  CAS  Google Scholar 

  18. Kreymann B, Williams G, Ghatei MA, Bloom SR . Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300–1304.

    Article  CAS  Google Scholar 

  19. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz P . Proceedings: radioimmunoassay of a new gut hormone-human pancreatic polypeptide. Gut 1976; 17: 393–394.

    Article  CAS  Google Scholar 

  20. Chelikani PK, Haver AC, Reidelberger RD . Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R39–R46.

    Article  CAS  Google Scholar 

  21. Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM . Effects of Exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 2011; 19: 121–127.

    Article  CAS  Google Scholar 

  22. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ . PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291: R367–R375.

    Article  CAS  Google Scholar 

  23. Koegler FH, Enriori PJ, Billes SK, Takahashi DL, Martin MS, Clark RL et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 2005; 54: 3198–3204.

    Article  CAS  Google Scholar 

  24. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 1332–1340.

    Article  CAS  Google Scholar 

  25. Kwak HH, Shim WS, Hwang S, Son MK, Kim YJ, Kim TH et al. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharm Res 2009; 26: 2504–2512.

    Article  CAS  Google Scholar 

  26. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559–569.

    Article  CAS  Google Scholar 

  27. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259–267.

    Article  CAS  Google Scholar 

  28. Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC . Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg 2008; 18: 648–651.

    Article  Google Scholar 

  29. Christou NV, Look D, Maclean LD . Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006; 244: 734–740.

    Article  Google Scholar 

  30. Gumbs AA, Pomp A, Gagner M . Revisional bariatric surgery for inadequate weight loss. Obes Surg 2007; 17: 1137–1145.

    Article  Google Scholar 

  31. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I . Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142: 621–632; discussion 632–635.

    Article  Google Scholar 

  32. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606–1616.

    Article  CAS  Google Scholar 

  33. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173–181.

    Article  CAS  Google Scholar 

  34. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249–254.

    Article  CAS  Google Scholar 

  35. Alvarez GC, Faria EN, Beck M, Girardon DT, Machado AC . Laparoscopic spleen-preserving distal pancreatectomy as treatment for nesidioblastosis after gastric bypass surgery. Obes Surg 2007; 17: 550–552.

    Article  Google Scholar 

  36. Clancy TE, Moore Jr FD, Zinner MJ . Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 2006; 10: 1116–1119.

    Article  Google Scholar 

  37. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ . A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002; 87: 1797–1804.

    Article  CAS  Google Scholar 

  38. Rudholm T, Wallin B, Theodorsson E, Näslund E, Hellström PM . Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept 2009; 152: 8–12.

    Article  CAS  Google Scholar 

  39. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120–5127.

    Article  CAS  Google Scholar 

  40. Proulx K, Cota D, Castañeda TR, Tschöp MH, D'Alessio DA, Tso P et al. Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. Am J Physiol Regul Integr Comp Physiol 2005; 289: R729–R737.

    Article  CAS  Google Scholar 

  41. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC et al. The role of CNS glucagon-like peptide-1 (7−36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000; 20: 1616–1621.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

WKF and MB were supported by the German Research Society (DFG), CleR by a Department of Health clinician scientist award, and ADM was supported by the Medical Research Council. Imperial College London receives support from the National Institute for Health Research Biomedical Research Centre funding scheme.

Author information

Author notes

  1. W K Fenske and M Bueter: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Investigative Medicine, Imperial Weight Centre, Imperial College London, London, UK

    W K Fenske, M Bueter, A D Miras, M A Ghatei, S R Bloom & C W le Roux

  2. Department of Internal Medicine I, Endocrine and Diabetes Unit, University Hospital Würzburg, Würzburg, Germany

    W K Fenske

  3. Division of Visceral and Transplantation Surgery, Department of Surgery, University Hospital, Zurich, Switzerland

    M Bueter

Authors
  1. W K Fenske
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Bueter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A D Miras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M A Ghatei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S R Bloom
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C W le Roux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C W le Roux.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fenske, W., Bueter, M., Miras, A. et al. Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. Int J Obes 36, 379–384 (2012). https://doi.org/10.1038/ijo.2011.126

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2011.126

Keywords

This article is cited by

Search

Advanced search

Quick links